CA
XENE icon

Clearstead Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Clearstead Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.67K Buy
+94
New +$5.22K ﹤0.01% 2154
2026
Q1 		– Sell
-1,215
Closed -$54.5K – 2860
2025
Q4 		$54.5K Buy
1,215
+829
+215% +$34.8K ﹤0.01% 1373
2025
Q3 		$15.5K Buy
386
+39
+11% +$1.37K ﹤0.01% 1758
2025
Q2 		$10.9K Buy
347
+129
+59% +$4.21K ﹤0.01% 1864
2025
Q1 		$7.31K Hold
218
– – ﹤0.01% 1687
2024
Q4 		$8.55K Hold
218
– – ﹤0.01% 1614
2024
Q3 		$8.58K Hold
218
– – ﹤0.01% 1613
2024
Q2 		$8.5K Buy
+218
New +$8.71K ﹤0.01% 1572

Other funds holding XENE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Clearstead Advisors's XENE Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 94 shares worth $5.67K. The stake represents ﹤0.01% of the portfolio and ranks #2154 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in XENE as recently as Q4 2025.

Clearstead Advisors first reported a position in XENE in Q2 2024 and has held it in 8 quarters since. The position peaked at $54.5K in Q4 2025. 103 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Clearstead Advisors held 94 shares of Xenon Pharmaceuticals worth $5.67K as of Q2 2026.
  • Xenon Pharmaceuticals was a new Clearstead Advisors position in Q2 2026.
  • Xenon Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2154 holding.
  • Clearstead Advisors first reported a position in Xenon Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • Clearstead Advisors's Xenon Pharmaceuticals position peaked at $54.5K in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.